Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

Clinical and Experimental Rheumatology

Volumn 31, Issue 4, 2013, Pages 538-545

  Miranda Filloy, J A ^a   Lopez Mejias R ^b   Genre, F ^b   Carnero Lopez B ^c   Ochoa, R ^b   de Terán, T Diaz ^d   Gonzalez Juanatey C ^a   Blanco, R ^b   Llorca, J ^e   Gonzalez Gay M A ^b  

^a HOSPITAL XERAL CALDE   (Spain)

^b Epidemiology Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF antibody infliximab; Atherosclerosis; Inflammation; Leptin; Visfatin

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA B27 ANTIGEN; INFLIXIMAB; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; RESISTIN; TRIACYLGLYCEROL;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; IRIDOCYCLITIS; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADIPOSE TISSUE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; CYTOKINES; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883596158     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. PETERS MJ, van der HORST-BRUINSMA IE, DIJKMANS BA, NURMOHAMED MT: Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 585-92.
2. PETERS MJ, VISMAN I, NIELEN MM et al.: Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 579-81.
3. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA et al.: The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-65.
4. PETERS MJ, van EIJK IC, SMULDERS YM et al.: Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37: 161-6.
5. BODNÁR N, KEREKES G, SERES I et al.: Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011; 38: 723-9.
6. MATHIEU S, GOSSEC L, DOUGADOS M, SOUBRIER M: Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 557-63.
7. BERG AH, SCHERER PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-49.
8. TILG H, MOSCHEN AR: Adypocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83.
9. OTERO M, LAGO R, GÓMEZ R, LAGO F, GÓMEZ-REINO JJ, GUALILLO O: Leptin: a metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect 2006; 19: 21-6.
10. GÓMEZ R, CONDE J, SCOTECE M, GÓMEZREINO JJ, LAGO F, GUALILLO O: What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011; 7: 528-36.
11. OTERO M, LAGO R, GOMEZ R et al.: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
12. PARK MC, CHUNG SJ, PARK YB, LEE SK: Proinflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis. Joint Bone Spine 2009; 76: 170-5.
13. TOUSSIROT E, STREIT G, NGUYEN NU et al.: Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007; 56: 1383-9.
14. SARI I, DEMIR T, KOZACI LD et al.: Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 1427-32.
15. DERDEMEZIS CS, FILIPPATOS TD, VOULGARI PV, TSELEPIS AD, DROSOS AA, KIORTSIS DN: Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clin Exp Rheumatol 2010; 28: 880-3.
16. FUKUHARA A, MATSUDA M, NISHIZAWA M et al.: Visfatin: a protein secreted by visceral fat that mimics the effect of insulin. Science 2005; 307: 426-30.
17. LAGO F, DIEGUEZ C, GOMEZ-REINO J, GUALILLO O: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313-25.
18. BRENTANO F, SCHORR O, OSPELT C et al.: Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrixdegrading activities. Arthritis Rheum 2007; 56: 2829-39.
19. MOSCHEN AR, KASER A, ENRICH B et al.: Visfatin an adipocytokine with pro-inflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-58.
20. LUK T, MALAM Z, MARSHALL JC: Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008; 83: 804-16.
21. BERNDT J, KLOTING N, KRALISCH S et al.: Plasma visfatin concentrations and fat depotspecific mRNA expression in humans. Diabetes 2005; 54: 2911-16.
22. HULEJOVÁ H, LEVITOVÁ A, KUKLOVÁ M et al.: No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clin Rheumatol 2012; 31: 67-71.
23. GONZALEZ-GAY MA, De MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
24. MIRANDA-FILLOY JA, LLORCA J, CARNEROLÓPEZ B, GONZÁLEZ-JUANATEY C, BLANCO R, GONZÁLEZ-GAY MA: TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012; 30: 850-5.
25. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F et al.: Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2012 Dec 13 [Epub].
26. van der LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
27. VIS M, NURMOHAMED MT, WOLBINK G et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-5.
28. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti-TNF-αlpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
29. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-αlpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
30. BRAUN J, van den BERG R, BARALIAKOS X et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
31. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
32. D'ANGELO S, PALAZZI C, CANTINI F et al.: Etanercept in spondyloarthopathies. Part II: Safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011; 29: 865-70.
33. PALAZZI C, D'ANGELO S, CANTINI F et al.: Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
34. HELDMANN F, BRANDT J, VAN DER HORSTBRUINSMA IE et al.: The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
35. SIERRA-JOHNSON J, ROMERO-CORRAL A, LOPEZ-JIMENEZ F et al.: Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 2007; 100: 234-9.
36. KARADUMAN M, OKTENLI C, MUSABAK U et al.: Leptin, soluble interleukin-6 receptor, C-reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atherosclerotic plaque. Clin Exp Immunol 2006; 143: 452-7.
37. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERJA A et al.: Anti-TNF-αlpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 222-8.
38. NICKLAS BJ, KATZEL LI, RYAN AS, DENNIS KE, GOLDBERG AP: Gender differences in the response of plasma leptin concentrations to weight loss in obese older individuals. Obes Res 1997; 5: 62-8.
39. KIM KJ, KIM JY, PARK SJ et al.: Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin Rheumatol 2012; 31: 1231-8.
40. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, GARCIA-UNZUETA MT et al.: Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-αlpha therapy. Clin Exp Rheumatol 2010; 28: 56-62.
41. MALESCI D, NIGLIO A, MENNILLO GA, BUONO R, VALENTINI G, La MONTAGNA G: High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 710-4.
42. PAPADAKIS JA, SIDIROPOULOS PI, KARVOUNARIS SA et al.: High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNF-αlpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009; 27: 292-8.
43. SETHI JK, VIDAL-PUIG A: Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005; 11: 344-7.
44. ZAHORSKA-MARKIEWICZ B, OLSZANECKA-GLINIANOWICZ M, JANOWSKA J et al.: Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-4.
45. KOWALSKA I, STRACZKOWSKI M, NIKOLAJUK A et al.: Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007; 22: 1824-9.
46. HAIDER DG, SCHALLER G, KAPIOTIS S, MAIER C, LUGER A, WOLZT M: The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-14.
47. GONZALEZ-JUANATEY C, LLORCA J, MIRANDA-FILLOY JA et al.: Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-93.
48. GONZALEZ-JUANATEY C, LLORCA J, AMIGO-DIAZ E, DIERSSEN T, MARTIN J, GONZALEZ-GAY MA: High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 1074-80.
49. GLADMAN DD, ANG M, SU L, TOM BD, SCHENTAG CT, FAREWELL VT: Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-5.
50. SAEKI H, SHIBATA S, TADA Y, KARAKAWA M, MINATANI Y, TAMAKI K: Psoriasis arthropathica associated with severe obesity showing high serum leptin level. J Dermatol 2009; 36: 364-6.
51. VALENTINI L, WIRTH EK, SCHWEIZER U et al.: Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009; 25: 172-81.
52. TUZUN A, UYGUN A, YESILOVA Z et al.: Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol 2004; 19: 429-32.
53. POPA C, NETEA MG, de GRAAF J et al.: Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009; 36: 724-30.